PharmaEngine Valuation
Is 4162 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4162 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4162 (NT$96.2) is trading below our estimate of fair value (NT$112.35)
Significantly Below Fair Value: 4162 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4162?
Key metric: As 4162 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 4162's PE Ratio? | |
|---|---|
| PE Ratio | 37.3x |
| Earnings | NT$370.14m |
| Market Cap | NT$13.82b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 12.1x |
| Enterprise Value/EBITDA | 25.6x |
| PEG Ratio | -1.4x |
Price to Earnings Ratio vs Peers
How does 4162's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 68.7x | ||
4728 Sunmax Biotechnology | 21.5x | n/a | NT$15.0b |
6712 Ever Supreme Bio Technology | 55.8x | n/a | NT$14.2b |
1783 Maxigen Biotech | 25.1x | n/a | NT$3.9b |
4169 TCM Biotech International | 172.4x | n/a | NT$3.4b |
4162 PharmaEngine | 37.3x | -26.3% | NT$13.8b |
Price-To-Earnings vs Peers: 4162 is good value based on its Price-To-Earnings Ratio (37.3x) compared to the peer average (68.7x).
Price to Earnings Ratio vs Industry
How does 4162's PE Ratio compare vs other companies in the Asian Biotechs Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 4162 is expensive based on its Price-To-Earnings Ratio (37.3x) compared to the Asian Biotechs industry average (33x).
Price to Earnings Ratio vs Fair Ratio
What is 4162's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 37.3x |
| Fair PE Ratio | 10.6x |
Price-To-Earnings vs Fair Ratio: 4162 is expensive based on its Price-To-Earnings Ratio (37.3x) compared to the estimated Fair Price-To-Earnings Ratio (10.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
YungShin Global Holding
NT$15.5b
Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.
3705
NT$58.10
7D
8.6%
1Y
27.7%
RBC Bioscience
NT$258.9m
Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.
6848
NT$19.95
7D
-0.7%
1Y
32.1%
Cenra
NT$6.0b
Engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals.
1701
NT$21.15
7D
0%
1Y
-8.8%